Clinical Trial Update: Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating oral SNC-102 for combat-related post-traumatic stress disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• SNC-102

Snippet

Sponsor: Synchroneuron Inc. | Conditions: Post-Traumatic Stress Disorders, Posttraumatic Stress Disorders | Phase 2 | Status: WITHDRAWN